Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar
Abstract
BACKGROUND: Acromegaly, a rare endocrine disorder characterised by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1), is often due to GH-secreting pituitary adenomas. Pasireotide, a second-generation somatostatin receptor ligand (SRL), binds to multiple somatostatin receptors (SSTRs) and offers a promising alternative for patients unresponsive to first-generation SRLs like octreotide and lanreotide.
CASE SERIES: This report examines five acromegaly patients treated with pasireotide in Qatar after the failure of a first-generation SRL to normalise IFG-1 levels. Patient 1, a 39-year-old male with hyperprolactinaemi+a and acromegaly who underwent multiple therapies including surgery and radiotherapy, showed tumour size reduction and IGF-1 control with pasireotide. Patient 2, 48-year-old male with a significant macroadenoma and prior cabergoline treatment, achieved partial biochemical control. He developed Type 2 diabetes mellitus, which was managed with metformin/sitagliptin. Patient 3, a 41-year-old male, experienced dramatic symptom resolution and weight loss after switching to pasireotide, significantly improving his quality of life, with a reduction in tumour size. Patient 4, 52-year-old female, despite initial side effects on pasireotide, achieved normalisation in IGF-1 levels and resolution of active symptoms, with a significant reduction in tumour size. Patient 5, a 38-year-old female, after persistent elevation of IGF-1 on octreotide, responded well to…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.